Edition:
India

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

68.17USD
23 May 2018
Change (% chg)

$0.34 (+0.50%)
Prev Close
$67.83
Open
$67.36
Day's High
$68.38
Day's Low
$67.35
Volume
5,090,318
Avg. Vol
8,105,784
52-wk High
$89.54
52-wk Low
$63.76

Chart for

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $107,268.80
Shares Outstanding(Mil.): 1,305.93
Dividend: 0.52
Yield (%): 2.53

Financials

BRIEF-Gilead Sciences Board Has Declared A Cash Dividend Of $0.57 Per Share Of Common Stock For Q2 Of 2018

* GILEAD SCIENCES INC - BOARD OF DIRECTORS HAS DECLARED A CASH DIVIDEND OF $0.57 PER SHARE OF COMMON STOCK FOR Q2 OF 2018 Source text for Eikon: Further company coverage:

02 May 2018

BRIEF-Gilead Sciences Reports Q1 EPS $1.17

* GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

02 May 2018

UPDATE 1-Gilead hepatitis C drug sales slump, shares fall 5 pct

May 1 Gilead Sciences Inc reported a lower quarterly profit on Tuesday as sales of its flagship hepatitis C drugs fell by a greater-than-expected 59 percent, sending shares of the biotechnology company down 5 percent.

02 May 2018

Gilead hepatitis C drug sales slump, shares fall 6 percent

May 1 Gilead Sciences Inc reported a lower quarterly profit on Tuesday as sales of its flagship hepatitis C drugs fell by a greater-than-expected 59 percent, sending shares of the biotechnology company down nearly 6 percent.

02 May 2018

BRIEF-Gilead And Verily Announce Scientific Collaboration

* GILEAD AND VERILY ANNOUNCE SCIENTIFIC COLLABORATION TO IDENTIFY AND UNDERSTAND IMMUNOLOGICAL AND MOLECULAR DRIVERS OF INFLAMMATORY DISEASES

01 May 2018

Gilead's three-drug HIV regimen wins European panel approval

Gilead Sciences Inc said on Friday its three-drug regimen to treat HIV infection was recommended for approval by a panel of the European Medicines Agency, paving the way for the biotech company to capture more sales in the multibillion-dollar market.

27 Apr 2018

Gilead's three-drug HIV regimen wins European panel approval

April 27 Gilead Sciences Inc said on Friday its three-drug regimen to treat HIV infection was recommended for approval by a panel of the European Medicines Agency, paving the way for the biotech company to capture more sales in the multibillion-dollar market.

27 Apr 2018

BRIEF-European CHMP Adopts Positive Opinion For Gilead's Biktarvy

* EUROPEAN CHMP ADOPTS POSITIVE OPINION FOR GILEAD'S BIKTARVY® (BICTEGRAVIR, EMTRICITABINE, TENOFOVIR ALAFENAMIDE) Source text for Eikon: Further company coverage:

27 Apr 2018

U.S. court upholds dismissal of $200 million Merck verdict against Gilead

A U.S. appeals court on Wednesday affirmed a ruling that pharmaceutical company Merck & Co dishonestly obtained patent rights and was not entitled to collect a $200 million infringement verdict it won against rival Gilead Sciences Inc.

26 Apr 2018

UPDATE 1-U.S. court upholds dismissal of $200 mln Merck verdict against Gilead

April 25 A U.S. appeals court on Wednesday affirmed a ruling that pharmaceutical company Merck & Co dishonestly obtained patent rights and was not entitled to collect a $200 million infringement verdict it won against rival Gilead Sciences Inc.

26 Apr 2018

Earnings vs. Estimates